Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Radicava
Pharma
Mitsubishi Tanabe models economic impact of IV-to-oral switch
The researchers describe a review of existing evaluations of the impact of oral formulations and their own model for quantifying the effect.
Nick Paul Taylor
Aug 2, 2022 7:40am
Hengrui, Merck-Kelun, Dr. Reddy's and more—Fierce Pharma Asia
May 20, 2022 9:15am
Oral version of Mitsubishi's ALS drug Radicava gets FDA blessing
May 13, 2022 9:31am
Radicava stalls in EU as skeptical regulators demand new ALS trial
May 31, 2019 12:19pm
New Mitsubishi Tanabe tool finds ALS care centers for patients
May 22, 2019 9:22am
Samsung BioLogics, Gardasil and more—FiercePharmaAsia
Nov 16, 2018 10:12am
